Artificial intelligence (AI) and bio-data technologies are rapidly emerging as key drivers in the pet healthcare industry. In particular, the feline chronic kidney disease (CKD) sector — long considered one of the most difficult areas for treatment and recovery — is drawing growing global attention as companies begin combining genetic analysis with AI-driven personalized healthcare solutions.
CKD is one of the most common diseases among aging cats. Once symptoms become visible, however, kidney function is often difficult to restore. As a result, the pet healthcare industry is increasingly shifting away from treatment-focused approaches toward preventive care based on early genetic risk assessment.
Pet healthcare technology company Greycoat Research announced on Sunday that it is expanding its “Personalized Precision Nutrition” platform by integrating genetic screening and AI-powered health data analysis. The company aims to evolve beyond a conventional supplement business into a long-term healthcare platform capable of providing individualized care based on genetic and biological data.
At the center of the company’s research is the AIM (Apoptosis Inhibitor of Macrophages) gene mutation. Recent international veterinary studies have suggested that mutations in the Exon 3 region of the feline AIM gene may be associated with kidney disease vulnerability and disease progression, fueling growing interest in AI-assisted genetic healthcare technologies for pets.
Greycoat Research said it is building a management system that pre-screens genetic risk groups and combines AI analytics with lifestyle patterns, health indicators, and disease progression data to provide customized nutritional care for individual cats. Rather than offering standardized dietary products, the company focuses on continuously optimizing nutrition and care schedules based on long-term biological data analysis.
The company is also advancing AI models capable of analyzing major kidney health indicators such as creatinine (CREA) and blood urea nitrogen (BUN), alongside feeding and behavioral data, to predict disease progression patterns over time. In the long run, Greycoat Research plans to develop a “smart care platform” where AI can automatically recommend nutritional programs and health management strategies tailored to each cat’s condition.
“Feline kidney disease is too complex to be managed simply through generic supplements,” said Yoon Jeong-eun, CEO of Greycoat Research. “The industry is moving toward a model where genetic vulnerabilities, biological indicators, and lifestyle data are analyzed together to predict long-term health risks and provide proactive care.”
The company is also expanding partnerships with external biotechnology firms. Greycoat Research is collaborating with PitterPetter, a pet genetic testing company, to integrate AIM gene-based screening data into its healthcare platform. The partnership aims to establish a full-cycle ecosystem connecting genetic testing, AI-based prediction, and personalized healthcare management.
Industry experts say the pet healthcare sector is increasingly following the same trajectory as human precision medicine. In North America and Europe, investment in startups combining AI, genomic analysis, and digital pet healthcare technologies has been rising steadily.
Greycoat Research has also accelerated its global expansion strategy. The company currently supplies products to 33 countries and recently completed the establishment of its U.S. subsidiary. It has also signed supply agreements with veterinary distributors in Türkiye as part of its broader push into global B2B veterinary hospital markets.
Industry observers believe that AI-powered predictive analytics and long-term healthcare platforms could become the next major growth engine for the global pet industry. As pet ownership continues to rise worldwide, the convergence of AI, genetic data, and preventive healthcare is expected to reshape the future of pet wellness and veterinary care.
